Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer

Metastatic breast cancer (MBC) remains an incurable disease, with the goals of care aimed at maximizing the patient’s duration and quality of life. Treatment options for MBC have become more efficacious and numerous. In addition to endocrine and chemotherapy agents, a number of targeted agents, incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz-Couselo, Eva, Pérez-García, José, Cortés, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3233277/
https://www.ncbi.nlm.nih.gov/pubmed/22162924
http://dx.doi.org/10.2147/OTT.S16392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3233277/
https://www.ncbi.nlm.nih.gov/pubmed/22162924
http://dx.doi.org/10.2147/OTT.S16392

Ejemplares similares